First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Latest Information Update: 25 Oct 2023
At a glance
- Drugs AMT 151 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Lung cancer; Male breast cancer; Malignant-mesothelioma; Ovarian cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Multitude Therapeutics
Most Recent Events
- 29 Jan 2023 Status changed from not yet recruiting to recruiting.
- 04 Jan 2023 Planned initiation date changed from 20 Dec 2022 to 30 Jan 2023.
- 02 Dec 2022 Planned initiation date changed from 1 Oct 2022 to 20 Dec 2022.